scholarly journals Erratum: The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development

Oncogene ◽  
2016 ◽  
Vol 35 (22) ◽  
pp. 2948-2948 ◽  
Author(s):  
A-L Joly ◽  
A Deepti ◽  
A Seignez ◽  
A Goloudina ◽  
S Hebrard ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Stem Cell Niche ◽  
Hsp90 Inhibitor ◽  
Intestinal Stem Cell ◽  
Disease Development ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Niche

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development

Oncogene ◽  
2015 ◽  
Vol 35 (22) ◽  
pp. 2842-2851 ◽  
Author(s):  
A-L Joly ◽  
A Deepti ◽  
A Seignez ◽  
A Goloudina ◽  
S Hebrard ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Stem Cell Niche ◽  
Hsp90 Inhibitor ◽  
Intestinal Stem Cell ◽  
Disease Development ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Niche

scholarly journals Regenerating Islet-Derived 3-Alpha (REG3A) Protects the Intestinal Stem Cell Niche to Control Acute Gastrointestinal Graft-Versus-Host Disease

2018 ◽  
Vol 24 (3) ◽  
pp. S69-S70
Author(s):  
Dongchang Zhao ◽  
Yeung-Hyen Kim ◽  
Joel K. Greenson ◽  
Mohammed S. Chaudhry ◽  
Matthias Hoepting ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Stem Cell Niche ◽  
Intestinal Stem Cell ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Niche

scholarly journals S892 INTESTINAL STEM CELL DAMAGE IN GRAFT-VERSUS-HOST DISEASE IS PRIMARILY CAUSED BY T-CELL DERIVED INTERFERON-GAMMA

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 401-402
Author(s):  
S.A. Jansen ◽  
S. Takashima ◽  
M.L. Martin ◽  
Y.-Y. Fu ◽  
J. Bos ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Interferon Gamma ◽  
Graft Versus Host Disease ◽  
Cell Damage ◽  
Intestinal Stem Cell ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Interferon-γ Mediates Direct Intestinal Stem Cell Damage in Gastrointestinal Graft-Versus-Host Disease

2018 ◽  
Vol 24 (3) ◽  
pp. S68
Author(s):  
Shuichiro Takashima ◽  
Joris Bos ◽  
Daniel Chandra ◽  
Suze A. Jansen ◽  
Margaret O'Connor ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Cell Damage ◽  
Interferon Γ ◽  
Intestinal Stem Cell ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 613
Author(s):  
Nidhi Sharma ◽  
Qiuhong Zhao ◽  
Bin Ni ◽  
Patrick Elder ◽  
Marcin Puto ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Tacrolimus Concentration ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
The Impact ◽  
Risk Of Relapse ◽  
Acute Graft

Acute graft versus host disease (aGVHD) remains a leading cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HSCT). Tacrolimus (TAC), a calcineurin inhibitor that prevents T-cell activation, is commonly used as a GVHD prophylaxis. However, there is variability in the serum concentrations of TAC, and little is known on the impact of early TAC levels on aGVHD. We retrospectively analyzed 673 consecutive patients undergoing allo-HSCT at the Ohio State University between 2002 and 2016. Week 1 TAC was associated with a lower risk of aGVHD II–IV at TAC level ≥10.15 ng/mL (p = 0.03) compared to the lowest quartile. The cumulative incidence of relapse at 1, 3 and 5 years was 33%, 38% and 41%, respectively. TAC levels at week 2, ≥11.55 ng/mL, were associated with an increased risk of relapse (p = 0.01) compared to the lowest quartile. Subset analysis with acute myeloid leukemia and myelodysplastic syndrome patients showed significantly reduced aGVHD with TAC level ≥10.15 ng/mL at week 1 and a higher risk of relapse associated with week 2 TAC level ≥11.55 ng/mL (p = 0.02). Hence, achieving ≥10 ng/mL during the first week of HCT may mitigate the risk of aGVHD. However, levels (>11 ng/mL) beyond the first week may be associated with suppressed graft versus tumor effect and higher relapse.

Sign in / Sign up

Export Citation Format

Share Document